The Scottish Medicines Consortium (SMC) has approved funding for four new therapies to be made available via NHS Scotland, Pharma Times reported on Tuesday.

Shire's (LON: SHP) Revestive (teduglutide) has been accepted as a treatment for paediatric onset short bowel syndrome (SBS) in children aged one to 17 years. The glucagon-like peptide-2 (GLP-2) analogue has been licensed to treat patients in a stable condition once their intestine has adapted post-surgery. It was rejected by the National Institute for Health and Care Excellence last year.

Two medicines targeting hepatitis C were approved by SMC. The first is Gilead's (NASDAQ: GILD) pan-genotypic therapy Vosevi (sofosbuvir-velpatasvir-voxilaprevir) to be used as a treatment for hepatitis C in adults who have not responded to previous treatment with targeted anti-viral therapy. It has also been approved to be used in adults with hepatitis C genotype 3 who have not had previous targeted anti-viral treatment.

Gilead's Epclusa (sofosbuvir-velpatasvir) has also been recommended as a treatment for hepatitis C for patients with genotype 1 or 4 infection. This means that patients with all hepatitis C genotypes can receive treatment on the NHS in Scotland.

Finally, Sanofi's (EPA: SAN) Kevzara (sarilumab) was approved as a treatment for rheumatoid arthritis. The human monoclonal antibody binds to the interleukin-6 receptor (IL-6R) helping to reduce inflammation associated with the disease.